Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
alpha-glucosidase I inhibitor
Celgosivir is an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. -
glucosidase I/II inhibitor
Deoxynojirimycin is a Maltase-glucoamylase (a-glucosidase I and II) inhibitor. It interferes with N-linked glycosylation. -
α-glucosidase inhibitor
Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage. -
alpha-glucosidase/alpha-1,6-glucosidase inhibitor
N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown. -
GCase inhibitor
Conduritol B epoxide is an irreversible covalently bound acid β-glucosidase (GCase) inhibitor. -
PTP1B Inhibitor
Caffeoyltryptophan is a competitive inhibitor of protein tyrosine phosphatase 1B (PTP1B), exhibiting an IC50 of 16.99 μM. Additionally, it demonstrates inhibitory effects on α-glucosidase, linoleic acid peroxidation, and hemolysis. This compound is primarily utilized in research related to type 2 diabetes, offering insights into metabolic regulation and potential therapeutic avenues. -
DPP-4 Inhibitor
Antidiabetic agent 2 is a potent DPP-4 inhibitor that effectively promotes glucose uptake. This compound also inhibits PTP-1B, α-amylase, and α-glucosidase, exhibiting IC50 values of 0.036, 0.042, 0.241, and 0.185 μM, respectively. By decreasing blood glucose levels, Antidiabetic agent 2 serves as a valuable tool for research focused on diabetes management and the modulation of glucose homeostasis. -
Phosphatase Inhibitor
Chrysophanol triglucoside is an anthraquinone with a specific inhibitory action on protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, demonstrating IC50 values of 80.17 µM and 197.06 µM, respectively. This compound is derived from Cassia obtusifolia and has potential applications in diabetes research, particularly in the study of glucose metabolism and insulin signaling pathways. -
α-Glucosidase Inhibitor
Guavinoside B is an orally active α-glucosidase inhibitor, exhibiting an IC50 of 0.21 mM. It demonstrates significant biological activity by upregulating the expressions of Nrf2, GCLC, and NQO1 while downregulating p-JNK expression and reducing intracellular reactive oxygen species levels. Guavinoside B effectively decreases serum TNF-α levels associated with Acetaminophen, alleviating hepatocellular infiltration and necrosis, and improving liver-related biochemical parameters. This compound is relevant for research in diabetes and Acetaminophen-induced liver injury. -
α-glucosidase inhibitor
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. -
α-glucosidase inhibitory activities
Tangshenoside I, isolated from the roots of Codonopsis lanceolata, exhibits weak α-glucosidase inhibitory activities in vitro with an IC50 of 1.4 mM. -
α-Glucosidase Inhibitor
Malabaricone B is a naturally occurring phenolic compound that functions as an α-glucosidase inhibitor, exhibiting an IC50 of 63.7 µM. This compound demonstrates significant biological activities, including anticancer, antimicrobial, antioxidant, and antidiabetic effects. It is suitable for research applications focused on metabolic regulation and the investigation of glycemic control. -
COX-1/HDAC/Tyrosinase Inhibitor
Gnetol is a bioactive phenolic compound isolated from the root of *Gnetum montanum* with diverse pharmacological properties. It potently inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 0.78 μM and exhibits histone deacetylase (HDAC) inhibitory activity. Gnetol is also a strong tyrosinase inhibitor, with an IC₅₀ of 4.5 μM against murine tyrosinase, leading to suppression of melanin biosynthesis. In addition to its antioxidant, antiproliferative, anticancer, and hepatoprotective effects, Gnetol modulates metabolic enzymes in a concentration-dependent manner, including α-amylase, α-glucosidase, and adipogenesis pathways, making it a promising candidate for research in oncology, dermatology, and metabolic disorders. -
Pancreatic Lipase/Acetylcholinesterase/Glutamic-oxaloacetic Transaminase 1/Alpha-glucosidase Inhibitor
Aspulvinone H is a potent inhibitor targeting pancreatic lipase, acetylcholinesterase, glutamic-oxaloacetic transaminase 1 (GOT1), and α-glucosidase, with IC50 values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It demonstrates key biological activities including inhibition of cancer cell proliferation, disruption of glutamine metabolism, and induction of apoptosis in cancer cells. Additionally, Aspulvinone H lowers postprandial blood glucose levels in mice and exhibits antibacterial properties against Staphylococcus aureus. This compound is suitable for research into pancreatic ductal adenocarcinoma, diabetes management, and infectious diseases caused by Staphylococcus aureus. -
α-Glucosidase Inhibitor
CKD-711 is an orally active aminooligosaccharide that functions as a potent inhibitor of α-glucosidase, with an IC50 of 78 μg/mL. It also demonstrates inhibitory effects against porcine intestinal maltase and sucrose, with IC50 values of 2.5 and 0.5 μg/mL, respectively. Additionally, CKD-711 exhibits selective antibacterial activity against Comamonas terrigena. This compound is valuable for research into infections and metabolic disorders, including diabetes. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-63 is a potent inhibitor of α-Glucosidase, displaying an IC50 value of 0.44 μM. Additionally, it inhibits human carbonic anhydrase II (hCA II) with a Ki of 7.0 nM. This compound is of interest for research applications focusing on glucose metabolism and enzymatic regulation in metabolic disorders. Its oral effectiveness enhances its utility in in vivo studies. -
PKCα Inhibitor
Leucosceptoside A is a phenylethanoid glycoside that functions as a selective inhibitor of Protein Kinase C alpha (PKCα). This compound demonstrates significant anti-hyperglycemic and anti-hypertensive effects and exhibits inhibitory activity against α-glucosidase, with an IC50 value of 19.0 μM. Leucosceptoside A is relevant for research into metabolic disorders and cardiovascular diseases, providing insights into therapeutic approaches targeting PKCα. -
α-glucosidase Inhibitor
1-Deoxynojirimycin hydrochloride is a potent α-glucosidase inhibitor, primarily utilized for modulating postprandial blood glucose levels. This compound demonstrates notable antihyperglycemic and anti-obesity effects, making it valuable in diabetes mellitus research. Additionally, 1-Deoxynojirimycin hydrochloride exhibits antiviral properties, contributing to its diverse applicability in metabolic and infectious disease studies. -
ChE Inhibitor
N-p-trans-Coumaroyltyramine is a natural phenolic amide compound that acts as an inhibitor of acetylcholinesterase (AChE) with an IC50 of 122 μM and α-glucosidase with an IC50 of 2.7 μM. It demonstrates significant anti-trypanosomal activity, exhibiting an IC50 of 13.3 µM against Trypanosoma brucei rhodesiense. This compound is valuable for research into neurodegenerative diseases such as Alzheimer's disease, as well as for studies focusing on trypanosomiasis. -
α-Glucosidase/HMG-CoA reductase Dual Inhibitor
Ganomycin I is a dual inhibitor targeting α-Glucosidase and HMG-CoA reductase. It demonstrates significant anti-diabetic properties and inhibits HIV protease, contributing to its potential as an antiviral agent. Additionally, Ganomycin I shows effectiveness in preventing osteoclastogenesis, making it a valuable reagent for research in diabetes and bone metabolism. -
α-Glucosidase I Inhibitor
Celgosivir hydrochloride is an α-glucosidase I inhibitor that demonstrates significant antiviral activity by inhibiting bovine viral diarrhoea virus (BVDV) with an IC50 value of 1.27 μM in in vitro assays. This compound is valuable for researchers studying viral infections and exploring potential therapeutic strategies through glycosidase inhibition. Its ability to modulate glycosylation processes makes it a relevant tool for biochemical and pharmacological investigations. -
Endoplasmic Reticulum α-glucosidase II (GluII) Inhibitor
ToP-DNJ is a specific inhibitor of endoplasmic reticulum α-glucosidase II (GluII), demonstrating an IC50 value of 9.0 μM. It selectively interferes with both catalytic reactions of GluII, showing enhanced activity in the initial conversion of di-glycosylated to mono-glycosylated glycans. Additionally, ToP-DNJ exhibits anti-DENV activity, making it a valuable tool for research into dengue virus infection and related glycobiology studies. -
Influenza Viru Inhibitor
SP187 hydrochloride is a host-targeting iminosaccharide that primarily inhibits endoplasmic reticulum glucosidase, rendering it effective against filovirus infections. This compound demonstrates antiviral activity, notably against the Dengue virus, in vivo. SP187 hydrochloride is a valuable tool for researchers investigating antiviral mechanisms and developing therapeutic strategies against viral infections. -
Glucosidase Inhibitor
Ganoderic acid Y is an α-glucosidase inhibitor, exhibiting an IC50 of 170 μM against yeast α-glucosidase. This compound demonstrates antiviral properties by inhibiting the replication of enterovirus 71 (EV71) through the disruption of the virus uncoating process. Ganoderic acid Y is relevant for research applications investigating glycosidase activity and antiviral strategies. -
α-Glucosidase Inhibitor
DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL, demonstrating significant broad-spectrum activity against SARS-CoV-2. It disrupts the endoplasmic reticulum-associated glycoprotein folding process, inhibiting proper processing of viral glycoproteins and consequently blocking viral particle formation and infection. DNJ-20 exhibits IC50 values as low as 1.49 μM against various SARS-CoV-2 variants, as well as HCoV-229E and HCoV-OC43. This inhibitor is suited for pan-coronavirus research applications. -
α-Glucosidase Inhibitor
Isosojagol is an α-Glucosidase inhibitor with an IC50 of 32.2 μM, demonstrating significant potential in modulating carbohydrate metabolism. Isolated from the roots of Dolichos trilobus, Isosojagol exhibits anti-inflammatory properties by inhibiting LPS-induced nitric oxide production in RAW264.7 cells. This reagent is relevant for research into fracture healing, soft tissue injuries, and rheumatoid arthritis, providing a valuable tool for understanding the underlying biological mechanisms. -
Tyrosinase/α-glucosidase Inhibitor
Pedalitin is a dual inhibitor of tyrosinase (IC50 = 0.28 mM) and α-glucosidase (IC50 = 0.29 mM). This compound demonstrates significant biological activity in the regulation of melanin production and glucose metabolism. Pedalitin is suitable for research applications exploring skin pigmentation disorders and metabolic diseases. -
Tyrosinase Inhibitor
Methyl rosmarinate is a noncompetitive inhibitor of tyrosinase, effectively isolated from Rabdosia serra, with an IC50 value of 0.28 mM for mushroom tyrosinase. Additionally, it demonstrates inhibitory activity against α-glucosidase. This compound is valuable for research in pigmentation, skin disorders, and carbohydrate metabolism. -
AChE Inhibitor
AChE-IN-20 is a potent acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 397.32 nM and a Ki value of 335.76 nM. In addition to its primary target, AChE-IN-20 exhibits significant inhibitory activity against human carbonic anhydrases I and II, and α-glucosidase, with IC50 values of 84.14 nM, 69.24 nM, and 52.08 nM, respectively. This compound is valuable for research into neurodegenerative diseases and enzymatic regulation, providing insights into potential therapeutic strategies. -
α-Glucosidase Inhibitor
(6-O-p-Coumaroyl)-β-D-glucopyranosyl-2-O-(4-hydroxybenzoyl)-4-O-β-D-glucopyranosyl-6-hydroxyphenylacetate functions as a selective α-glucosidase inhibitor, exhibiting an IC50 of 10.53 μg/mL. This compound demonstrates significant anti-hepatic fibrosis and anti-diabetic activities, while also inhibiting the proliferation of mouse hepatic stellate cells (t-HSC/Cl-6) with an IC50 of 109.2 μg/mL. Isolated from the ester derivatives of Impatiens balsamina L. flowers, it serves as a valuable reagent for research focusing on hepatic fibrosis and type 2 diabetes. -
ER α-glucosidases Inhibitor
IHVR-11029 is a potent small molecule inhibitor of ER α-glucosidases, demonstrating an EC50 of 0.09 μM. This compound is primarily utilized in research for exploring glucosidase enzymatic activity and its implications in metabolic disorders. Its specificity and efficacy make it a valuable tool for studies investigating glycosylation processes and related pathways. -
α-glucosidase Inhibitor
CM-10-18 is a potent inhibitor of α-glucosidases I and II, demonstrating significant activity in vitro and in animal models. This compound also exhibits antiviral properties by inhibiting dengue virus (DENV) infection in cultured human cells, while effectively reducing peak viremia in mice. CM-10-18 is valuable for research applications related to glycosidase inhibition and viral pathogenesis. -
α-Glucosidase Inhibitor
α-Glucosidase-IN-5 is a potent α-glucosidase inhibitor, exhibiting an IC50 of 57.9 µM. This compound is valuable for studying the modulation of carbohydrate metabolism and has potential applications in diabetes mellitus research. By inhibiting α-glucosidase, α-Glucosidase-IN-5 may aid in the investigation of glycemic control and the development of therapeutic strategies for diabetes management. -
α-glucosidase Inhibitor
Gallacetophenone is a potent inhibitor of α-glucosidase, displaying an IC50 value of 408.6 μM. This compound demonstrates synergistic effects on mammalian α-glucosidase when combined with 1-Deoxynojirimycin at elevated concentrations. Gallacetophenone is valuable for research into metabolic disorders, particularly type 2 diabetes, by facilitating the understanding of carbohydrate metabolism and its implications in glycemic control. -
α/β-Glucosidases Inhibitor
Castanospermine is a natural alkaloid primarily recognized for its role as an α/β-glucosidase inhibitor. This compound exhibits significant biological activities, including anti-inflammatory and antiviral properties, as well as the potential to impede metastatic progression in prostate cancer. Additionally, Castanospermine has applications as an immunosuppressant, proving useful in preventing transplant rejection. Its diverse functionalities make it a valuable tool in various areas of biochemical research. -
α-glucosidase I Inhibitor
Kojibiose is an α-glucosidase I inhibitor that functions as an orally active prebiotic disaccharide. It specifically inhibits the activity of α-glucosidase I, promoting the proliferation of beneficial gut bacteria such as Bifidobacterium and lactic acid bacteria. Additionally, kojibiose serves as a low-calorie sweetener that enhances iron absorption and exhibits antitoxic properties. In vivo studies demonstrate its ability to reduce hepatic expression of inflammatory markers, highlighting its potential applications in metabolic and gastrointestinal research. -
ColA Inhibitor
4',5-Dihydroxyflavone is a potent inhibitor of collagenase A (ColA), with an IC50 value of less than 1 μM. This flavonoid compound also shows inhibitory activity against α-glucosidase and soybean lipoxygenase-1, making it valuable in biochemical research. Its applications include studies focused on anti-toxicity and anti-diabetes, highlighting its potential therapeutic benefits in metabolic and inflammatory disorders. -
Tyrosinase Inhibitor
Kushenol A, a non-competitive inhibitor of tyrosinase, effectively blocks the conversion of L-tyrosine to L-DOPA, with IC50 and Ki values of 1.1 μM and 0.4 μM, respectively. Isolated from the root of Sophora flavescens, Kushenol A exhibits antioxidant properties and also inhibits alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase. This compound is valuable for research focused on skin whitening and anti-aging applications due to its enzyme inhibitory effects. -
Glucosidase Inhibitor
Gitogenin is a natural steroid derived from the plant Tribulus longipetalus, serving as a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and α-glucosidase. It exhibits an IC50 of 0.69 μM for UGT1A4 using trifluoperazine as a substrate, and an IC50 of 37.2 μM for α-glucosidase. Gitogenin does not interfere with the activities of major human cytochrome P450 isoforms, making it a valuable reagent for studies in metabolic enzyme pathways and potential therapeutic applications related to glycemic control. -
Glycosidase Inhibitor
Cedryl acetate is a tricyclic sesquiterpene with notable α-glucosidase inhibitory activity. This compound is isolated from the plant Cunninghamia lanceolata and is valuable in research focused on carbohydrate metabolism and glycosidase inhibition. Its biological activity makes it an important tool for studying metabolic disorders and potential therapeutic interventions. -
Glucosidase Inhibitor
Kaempferol 3-O-gentiobioside is a flavonoid that functions as an α-glucosidase inhibitor. Isolated from the leaves of C. alata, this compound demonstrates significant antidiabetic activity by inhibiting carbohydrate enzyme activity, with an IC50 value of 50.0 µM. It serves as a valuable tool for research into glucose metabolism and diabetes treatment applications. -
Glycosidase Inhibitor
Glycyrrhisoflavone is a potent α-glucosidase inhibitor that acts primarily by blocking the enzyme's activity, thereby modulating carbohydrate metabolism. This natural prenylflavonoid exhibits significant biological activity, making it useful in research related to diabetes management and metabolic disorders. Its ability to influence glycemic control highlights its potential applications in pharmacological studies and nutraceutical development. -
Alpha-glucosidase Inhibitor
Valiolamine is an aminocyclitol that functions as an alpha-glucosidase inhibitor. It exhibits significant inhibitory activity against porcine intestinal sucrase and maltase, with Ki values of 30 nM and 350 nM, respectively. This compound is valuable for research applications focused on carbohydrate metabolism, specifically in studying the modulation of glucose absorption and the potential therapeutic approaches to disorders such as diabetes. -
α-Glucosidase Inhibitor
Panasenoside is a flavonoid that acts as an α-glucosidase inhibitor. Derived from Lilium pumilum DC, it has demonstrated significant inhibitory activity against α-glucosidase, making it a valuable tool for research on carbohydrate metabolism and related disorders. This compound is relevant for studies investigating diabetes management and the modulation of postprandial blood glucose levels. -
α-Glucosidase Inhibitor
β-Hydroxypropiovanillone is an α-glucosidase inhibitor that demonstrates significant concentration-dependent inhibitory effects on this enzyme. With an IC50 value of 257.8 μg/mL, it is useful for studying carbohydrate metabolism and potential therapeutic applications in managing postprandial hyperglycemia. This compound may serve as a valuable research tool in the exploration of diabetes and related metabolic disorders. -
α-glucosidase Inhibitor
Magnoloside B is an α-glucosidase inhibitor with an IC50 value of 0.69 mM, derived from the stem bark of Magnolia officinalis. It exhibits moderate inhibitory activity against MGC-803 and HepG2 cancer cell lines. This compound is of significant interest for research applications related to cancer and diabetes. -
α-amylase/α-glucosidase/Acetylcholinesterase Inhibitor
Kaempferol-3,7-di-O-β-glucoside is a flavonol that acts as an inhibitor of α-amylase, α-glucosidase, and acetylcholinesterase. This compound has demonstrated protective effects on differentiating neuronal cells, specifically SH-SY5Y, against injury induced by Amyloid β peptide. Its enzyme inhibitory properties and neuroprotective effects indicate potential applications in Alzheimer's disease research and therapeutics.
